KRT17 and carcinoma: With this arbitrary cut-off in mind, studies in cervical adenocarcinoma [23], HNSCC [24,41], colorectal [55], esophageal [56,57], gallblader [58,59], and pancreatic [31,83] carcinoma suggest a high clinical utility for K17 as a negative prognostic biomarker.